TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has signed an agreement with IDIS, a private, U.K.-based company, to administer a Named Patient Program for Ceplene®, EpiCept’s proprietary therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission. Under this agreement, Ceplene is now available on a named patient basis in Europe in advance of its commercial launch later this year, as well as in the key worldwide markets including South America, Japan, Australia, Israel and Canada.
